Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.
We have addressed the safety of alum-adsorbed BBG2Na, a recombinant respiratory syncytial virus (RSV) subunit vaccine, in infant macaques. Animals received two vaccinations, and were challenged 4 months later with RSV. In two of four BBG2Na-vaccinated animals, specific IL-13 producing T cells were detected. Upon challenge, low level pulmonary eosinophilia was observed in the same two animals. Although the levels of these responses were substantially lower than those observed in the FI-RSV controls, these data suggest that more extensive studies focusing on immunopathological safety of alum-adsorbed BBG2Na in non-human primates would be required before proceeding to clinical trials in seronegative infants.
de Waal
Leon
L
Department of Virology, Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
Power
Ultan F
UF
Yüksel
Selma
S
van Amerongen
Geert
G
Nguyen
Thien N
TN
Niesters
Hubert G M
HG
de Swart
Rik L
RL
Osterhaus
Albert D M E
AD
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D018793:Interleukin-13 / Q000097:blood; D008252:Macaca fascicularis; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014611:Vaccination
D000914:Antibodies, Viral; C472186:BBG2Na vaccine; D007074:Immunoglobulin G; D018793:Interleukin-13; D022261:Respiratory Syncytial Virus Vaccines